大麻与大麻素在终末期肾病及早期慢性肾脏病中的应用
本文综述了医用大麻用于管理晚期慢性肾脏病(CKD)和终末期肾病(ESRD)患者常见症状(慢性疼痛、恶心呕吐、厌食恶病质、瘙痒)的现有证据,并讨论医用和娱乐性大麻使用的潜在健康影响。肾内科医生应了解大麻使用对患者群体的潜在影响,需进一步研究肾脏内源性大麻素系统及大麻使用对肾脏病结局的影响。
要点
- 晚期CKD和ESRD患者症状负担重,医用大麻可能用于管理慢性疼痛、恶心呕吐、厌食恶病质和瘙痒。
- 肾内科医生应了解大麻使用对CKD和ESRD患者的潜在影响,需进一步研究其风险与获益。
核心结论
- 大麻使用正变得主流,肾内科医生应了解其对晚期CKD和ESRD患者的潜在影响。
- 需进一步研究肾脏内源性大麻素系统、大麻使用对肾脏病结局的影响以及医用大麻对晚期CKD和ESRD症状的风险与获益。
研究设计与样本
- 综述文章,回顾医用大麻用于管理晚期CKD或ESRD患者常见症状的现有证据,并讨论医用和娱乐性大麻使用的潜在健康影响。
主要发现
- 晚期CKD和ESRD患者常报告慢性疼痛、恶心呕吐、厌食恶病质和瘙痒等症状,因药物副作用常治疗不足。
临床怎么用
- 肾内科医生应了解大麻使用对CKD和ESRD患者的潜在影响, regardless of personal, social, and political beliefs。
局限性
- 需进一步研究肾脏内源性大麻素系统、大麻使用对肾脏病结局的影响以及医用大麻对晚期CKD和ESRD症状的风险与获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Marijuana is the most commonly used recreational drug in the United States, and legal recreational and medicinal use has gained public acceptance during the last decade. Twenty-nine US states have established medical marijuana programs, 8 of which have also legalized recreational marijuana, and Canada is expected to legalize recreational marijuana in 2018. Advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) are chronic conditions with significant associated morbidity and mortality. Patients experience substantial symptom burden that is frequently undertreated due to adverse medication side effects. This article reviews the available evidence for the use of medical marijuana to manage chronic pain, nausea/vomiting, anorexia/cachexia, and pruritus, all of which are frequently reported by patients with advanced CKD or ESRD. Potential adverse health effects of medical and recreational marijuana use are also discussed. Regardless of personal, social, and political beliefs, marijuana use is becoming mainstream, and nephrologists should be aware of the potential impact on our patient population. Further research is warranted to investigate the renal endocannabinoid system, the impact of marijuana use on kidney disease outcomes, and the risks and benefits of medical marijuana use on symptoms of advanced CKD and ESRD.
引用
- Rein JL, Wyatt CM. Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD. Am J Kidney Dis. 2017. PMID: 28811049. doi:10.1053/j.ajkd.2017.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。